ARTICLE
Key Takeaways | Clinical Research Technology (ClinTech)
July 16, 2024
Read time: 4 min
During this session, the panelists discussed how stakeholders in the clinical research market can leverage new technologies to better identify subjects, optimize trial conduct and reduce costs. For example, common use cases of artificial intelligence (AI) in research include automating administrative and documentation tasks. Panelists also discuss the role of technology in curating data to power clinical trials. Challenges remain in implementing research-focused technology tools, especially as trials increase in size and patients remain concerned about large collections of sensitive health data.
Session panelists:
- Nathan Cohen, Vice President, Norwest VenHture Partners
- Jennifer Geetter, Partner, McDermott Will & Emery
- Raj Kothari, Senior Vice President, Jefferies
- Seungtaek Lee, Vice President of Strategic Provider Partners, ConcertAI
- Alexander Saint-Amand, Chief Executive Officer and Co-Founder, Topography Health
- Moderator: Kevin Sullivan, Partner, McDermott Will & Emery
Top takeaways included:
- Research Technology Can Address Pain Points in Research; Persistent Hurdles in Implementation. Time, cost, patient recruitment and increasing complexity in study design – present ongoing and new challenges impacting clinical research. Technology has a key role to play in minimizing these challenges. For pharmaceutical companies, bringing a product to market requires massive investment and can involve a long and uncertain development runway. One persistent frustration is difficulty with patient enrollment. The companies able to deploy technology to address these concerns include Contract Research Organizations (CROs), large technology companies and, of most interest to investors lately, independent technology providers that take a community lens, independently serving CROs and sponsors to help conduct trials more efficiently. To implement effective technology solutions, stakeholders need to: a) invest in sophisticated data tracking solutions; b) consider the implementation hurdles of multiple point of care solutions for overstressed health system CISOs and CTOs; c) be sensitive to and address privacy concerns and cyber threats; and d) consider user-friendly tools that can be understood by subjects.
- AI Will Play an Increasingly Important Role as Trials Become More Focused on Big Data Initiatives. For AI to add value to the research sector, the data training AI must be reliable and fit for purpose. Stakeholders that executive strategic partnerships to harness well-curated EHR and other data sources and implement effective strategies to both be a data provider and data ingester will see strategic advantages. With appropriately designed and tested AI tools, technology can be deployed to accelerate patient matching to find candidates that meet the study’s criteria, with lower screening failure rates, and can be used to accelerate drug development. IRBs do need additional training to understand AI and its role in clinical research.
- Investor Funding in Cutting-Edge Technologies, but Also in Proven Tools, Will Continue. In the next year, investors will continue to seek out exciting new technologies, such as wearable devices that can make patient data easier to transmit for real-world clinical trials and platforms that can make informed consent easier for patients to understand with videos and other interactive features. Because large technology companies have run into stumbling blocks when migrating different tech tools, investors are also interested in starting new businesses organically with technology that is interoperable and has data-linking capabilities. There is an interest in data review solutions, with some emerging in risk-based quality management or monitoring. In addition to state-of-the-art products, dollars will continue to flow toward defensive, proven, profitable businesses in the research space, such as Electronic Clinical Outcome Assessment tools and Interactive Response Technology.

Message Received: Trade Secret Law Damages Available for Sales Outside US
ARTICLE
Message Received: Trade Secret Law Damages Available for Sales Outside US
Jul 18, 2024
Read time: 4 min
The US Court of Appeals for the Seventh Circuit affirmed, in a matter of first impression, a district court’s decision to apply trade secret law extraterritorially and award trade secret damages for foreign sales while also finding that the copyright damages award needed to be reduced to eliminate foreign sales. Motorola Solutions, Inc. v. Hytera Communications Ltd., Case Nos. 22-2370; -2413 (7th Cir. July 2, 2024) (Hamilton, Brennan, St. Eve., JJ.)
Motorola Solutions and Hytera compete globally in the market for two-way radio systems. Motorola spent years and tens of millions of dollars developing trade secrets embodied in its line of high-end digital mobile radio (DMR) products. Hytera struggled to overcome technical challenges to develop its own competing DMR products. After failing for years, Hytera hatched a plan to “leap-frog Motorola” by stealing its trade secrets. Hytera, headquartered in China, hired three engineers from Motorola in Malaysia, offering them high-paying jobs in exchange for Motorola’s proprietary information. Before the engineers left Motorola, acting at Hytera’s direction, they downloaded thousands of documents and computer files containing Motorola’s trade secrets and copyrighted source code. Hytera relied on the stolen material to develop and launch a line of DMR radios that were functionally indistinguishable from Motorola’s DMR radios. Hytera sold these DMR radios in the United States and abroad.
Motorola sued Hytera for copyright infringement and trade secret misappropriation. The jury found that Hytera had violated both the Defend Trade Secrets Act of 2016 (DTSA) and the Copyright Act. The jury awarded compensatory damages under the Copyright Act and both compensatory and punitive damages under the DTSA for a total award of $765 million. The district court later reduced the award to $544 million, which included $136 million in copyright damages and $408 million in trade secrets damages. Hytera appealed.
Hytera conceded liability and instead challenged the damages award under both the Copyright Act and the DTSA. Among other things, Hytera argued that copyright and trade secret damages should not have been awarded for its sales outside the US. With respect to the copyright award, the Seventh Circuit agreed that Motorola failed to show a domestic violation of the Copyright Act and therefore was not entitled to recover damages for any of Hytera’s foreign sales of infringing products as unjust enrichment. Specifically, to show a domestic violation of the Copyright Act, Motorola had asserted that its code was copied from servers based in Chicago. While the district court accepted Motorola’s argument, the Seventh Circuit found that this factual finding lacked adequate support in the record, citing Motorola’s expert’s admission that there was no evidence of downloads from the Chicago servers. The Court instead found that given the location of the employees in Malaysia, it was likelier that the code was downloaded from Motorola’s Malaysia server. The Court therefore reversed the $136 million copyright award and remanded with instructions to limit the copyright award to Hytera’s domestic sales of infringing products.
The Seventh Circuit affirmed with respect to the trade secret award. Like the Copyright Act, the DTSA is subject to a presumption against extraterritoriality. The presumption can be rebutted under a two-step framework, which evaluates (1) whether the relevant statute gives a clear, affirmative indication that it applies extraterritorially, and if so, (2) what limits Congress has placed on its foreign application. Recognizing that this was a question of first impression for the Seventh Circuit (and as far as the Court could tell, any circuit), the Court turned to the statutory interpretation and determined that in enacting the DTSA, Congress was concerned with actions taking place outside of the US in relation to the misappropriation of US trade secrets when it passed the DTSA. As a result, the Court concluded that the DTSA applies extraterritorially, and that the district court did not err by awarding Motorola relief based on Hytera’s worldwide sales regardless of where the illegal activity occurred. The Court therefore affirmed the trade secret award.

Protecting employees’ tax position after a spin-off
ARTICLE
Protecting employees’ tax position after a spin-off
July 17, 2024
Read time: 6 min
Spin-offs have become increasingly popular with innovative companies as a method of unlocking shareholder value, but the transaction is not always tax-free, particularly for international employees holding equity awards or shares.
The ability to obtain tax-free treatment in the United States for both the company and shareholders in a spin-off is often attractive. However, the transaction is not always tax-free for shareholders located outside the US. When local country criteria are not met, the distribution of spin-co shares is taxable for shareholders.
Significantly, employees holding equity awards and company shares can be negatively affected by a spin-off, which can have a significant impact on morale at a very sensitive time in a spin-co’s evolution.
Companies generally take one of two approaches when adjusting equity awards in a spin-off: either a basket approach, where employees hold equity awards from both companies; or a concentration approach, where employees only retain equity awards from their post-spin employer. The basket approach raises more local tax and securities compliance issues than the concentration approach as the employee is holding awards from a company that is not their employer.
“Long” shares held by employees in an employer’s plan raise additional issues. The applicable tax analysis mirrors the analysis applicable to shareholders generally, which may or may not be taxable upon distribution, depending on the country. However, the tax result may differ when the shares are held in a trust or where the employee does not yet have full ownership of the shares. In certain cases, a local tax ruling should be submitted, potentially providing the employees with more favorable tax treatment than regular shareholders.
Tax-qualified equity awards also require consideration as the tax-advantaged treatment may be lost for the employees in many countries. For example, in the United Kingdom, Share Incentive Plans (SIPs) and Company Share Option Plans (CSOPs) are common equity awards and a spin-off impacts them differently.
When an employee holds shares in a SIP for five years, the employee may sell the shares without paying income tax or national insurance contributions. However, when a spin-off transaction does not meet the UK “demerger” rules for a tax-free spin-off, the SIP participants will be subject to taxation on the value of the distributed spin-co shares when they are distributed.
If an employee exercises CSOP options three or more years after grant, that employee doesn’t pay income tax at exercise for the difference between the exercise price and the current fair market value of the shares. Any adjustment of the CSOP awards results in the loss of tax-qualified treatment, subjecting the employee to income taxation when the options are exercised. Employees who have already met the three year requirement may therefore prefer to exercise the awards prior to the spin-off.
In most cases, particularly if the communication occurs shortly before the spin-off, employees do not fully understand the ramifications until it is too late to mitigate the tax impact. To avoid this, companies should communicate the tax implications to employees well before the spin-off, taking into account that preparing the analysis, and the requirements for restructuring the employee workforce prior to spin, often take significantly longer than expected.

Key Takeaways | Clinical Trial Site Management Organizations (SMOs)
ARTICLE
Key Takeaways | Clinical Trial Site Management Organizations (SMOs)
July 16, 2024
Read time: 5 min
During this session, the panelists discussed the role that SMOs and dedicated clinical trial sites (Site Platforms) play within the life sciences industry, what makes them attractive to investors, and the key criteria investors evaluate when considering opportunities to back or acquire a Site Platform). They also discussed recent market and legal developments that Site Platforms and investors alike should be aware of, including newer players to the space such as integrated research organizations (IROs) and the scrutiny of private equity in healthcare by lawmakers and regulators.
Session panelists:
- Nick Amigone, Partner, Amulet Capital Partners
- Kyle Burtnett, CEO, Headlands Research
- Linda McCarty, Co-Founder and Chief Legal Officer, Javara
- John Riddle, Managing Director, Brown Gibbons Lang & Company
- Moderator: Jiayan Chen, Partner, McDermott Will & Emery
Top takeaways included:
- Investors Are Excited by Site Platforms Because of Their Unique Position in the Industry and Lack of Reliance on Third-Party Payor Reimbursement. Site Platforms have features reflecting the life sciences/pharma services sector and traditional provider sector (e.g., physician practices or ambulatory businesses). While their customer base comprises life sciences companies, dedicated clinical trial sites have structures and operational characteristics that are reminiscent in many ways of managed physician practice platforms. Site Platforms also have the advantage of not being exposed to the risks and operational challenges associated with government and other third-party payor reimbursement. The life sciences sector continues to devote substantial resources to R&D. For these reasons, the clinical trial site space is an enticing area for investors.
- Diverse Patient Access, Consistency Across Sites, and Efficiency Are Compelling for Investors. When evaluating whether to invest in a Site Platform, investors will consider the Site Platform’s ability to operate uniformly across its various locations (as applicable) and opportunities to enhance such consistency post-closing, which may include centralizing functions to better balance the burdens on specific sites. Additionally, having access to a large volume of patients is attractive, but it is important for the Site Platform to be able to identify and recruit diverse patient populations, especially in communities where the disease prevalence is high and given FDA’s focus on improving diversity in clinical trials. Some Site Platforms have successfully enlisted community champions who are representative of the patient population or speak their language to engage with these communities, build trust and boost enrollment in trials. Investors may also focus on the Site Platform’s efficiency, which includes the pace at which it can identify eligible participants.
- When Scaling a Site Platform, Focus on Quality. Robust quality assurance programs are key for Site Platforms as they grow their operations and acquire additional sites. This includes standardized policies, procedures, training, and other infrastructure to ensure quality and consistency across the organizations and deployment of applicable best practices; regular internal monitoring to evaluate metrics, assess compliance with regulatory, sponsor, and internal requirements and implement remediation activities as necessary; and the involvement of experienced legal and operational subject matter experts to guide the sites. Study subject access and efficiency are certainly important, but Site Platforms should focus first on building and implementing such quality assurance infrastructure across sites, particularly as studies become increasingly complex.
- IROs Have Unique Advantages. An IRO is a type of SMO that is embedded within hospitals, physician practices, and other provider organizations and supplies the entire clinical trial infrastructure that the provider will need to successfully run a clinical trial program, excluding the principal investigator (PI). IROs may have access to the provider’s electronic medical records system at the point of feasibility, allowing the IRO to assess whether the study is right for the provider before moving forward. This has the added benefit of allowing the IRO to identify patients from the provider’s existing patient population rather than recruit externally. An IRO may enter into a triparty contract with the provider and the sponsor (or contract research organization) and has authority to negotiate on behalf of the provider, which makes negotiating terms and committing to an enrollment headcount easier, because the IRO has systematized the contract review process and has visibility into study feasibility. IROs offer an attractive option to providers that otherwise do not have the resources or appetite to build a sophisticated research infrastructure on their own.
- Private Equity-Backed Site Platforms Have Largely Escaped Recent Scrutiny But Should Stay Vigilant. Regulators, lawmakers and several state attorneys general have upped their scrutiny of private equity in physician practice management. So far, the clinical research industry has been largely spared from the resulting governmental pressures, but Site Platforms should pay attention to these developments and stay prepared. For now, Site Platforms should focus on tracking reliable data that can show the organization is adding value and resulting in better outcomes for patients and for the healthcare system as a whole.

Pharma and MedTech Services Investment Summit 2024
ARTICLE
Pharma and MedTech Services Investment Summit 2024
July 16, 2024
Read time: 2 min
The inaugural Pharma and MedTech Services Investment Summit brought together C-suite executives, senior private equity professionals, investment bankers and other industry leaders for a deep dive into the investment opportunities and emerging trends shaping Pharma and Device Services – 2024’s hottest sector.
Check out the key takeaways below for insights from the summit.
Click on the links below to view key takeaways from the Pharma and MedTech Services Investment Summit 2024. Key takeaways will be posted as they become available.
Plenary Sessions:

Key Takeaways | Medical Communications and Market Access
ARTICLE
Key Takeaways | Medical Communications and Market Access
July 16, 2024
Read time: 3 min
During this session, the panelists discussed medical communications and market access with a particular focus on commercialization. The discussion focused on how firms are leveraging technology and AI to build brands, drive product launches, conduct product pricing, and bring products to providers and end users. The panelists also highlighted the business outlook and other investment strategies.
Session panelists:
- Brian Fox, President, Chief Growth Officer, Klick Health
- Paul Hepper, Managing Director, Harris Williams
- Cynthia Hwang, General Manager, Riparian (an Envision Pharma Group company)
- Jon Maschmeyer, Partner, Permira
- Bret Tenenhaus, Principal, Great Point Partners
- Moderator: Jamie Ravitz, Partner, McDermott Will & Emery
Top takeaways included:
- Product Launches Play a Crucial Role in Driving Commercialization Within the Pharmaceutical Industry. There is a noticeable shift toward integrated marketing strategies that focus on medical information dissemination and patient access. Greater collaboration across different functions within pharmaceutical companies aims to create a unified patient experience, supported by data analytics and technological infrastructure.
- AI Is an Impactful Tool That Will Be Adopted by Current Industry Players. Commercial AI solutions are expected to increase in the pharmaceutical and medical technology (medtech) sectors. While AI can enhance job satisfaction and efficiency, human oversight remains necessary for compliance.
- Data and Technology Are Critical Subsectors Within Pharmaceutical and Medtech Services. Data is essential for winning service revenue, both externally and for internal efficiency. Opportunities exist for process enhancements to minimize revenue leakage risks. For example, data analytics can help identify misapplied discounts on claims, and predictive analytics can help support decision-making.
- Investors Evaluate Pharmaceutical and Medtech Companies Based on Growth Potential, Business Model Resilience and Financial Performance. While interest rates are elevated, there is still plenty of debt capital available.
- Take Advantage of Industry Diversification. Smaller patient populations have driven funding into small- and mid-sized pharmaceutical companies. There has been continued growth in oncology and rare disease markets and reduced reliance on large sales forces due to targeted marketing efforts.
- Looking Ahead, Pharmaceutical and Medtech Companies Are Facing Market Access and Communications Challenges. Large pharmaceutical companies, for example, are cutting budgets. In addition, Medicare drug impact programs will continue to impact available research and development funding.

Key Takeaways | Pharma and MedTech Manufacturing and Contract Development
ARTICLE
Key Takeaways | Pharma and MedTech Manufacturing and Contract Development
July 16, 2024
Read time: 3 min
During the session, the panelists discussed investment strategies in the Contract Development and Manufacturing Organization (CDMO) space, emphasizing factors like supply and demand dynamics, quality control, and the impact of the BIOSECURE Act on manufacturing trends.
Session panelists:
- Ritu Dhami, President, Network Partners Group
- Elizabeth Hickman, Chief Business Officer, AustinPx
- Kurt Orlofski, Chief Executive Officer, PAI Pharma
- Michael Reslinski, Managing Director, Healthcare and Life Sciences, Sixth Street
- Katherine Wood, Partner, TPG Capital
- Moderator: Krist Werling, Partner, McDermott Will & Emery
Top takeaways included:
- Think Strategically About CDMO Investments. Investors in the CDMO space must adopt a strategic mindset. First, innovation plays a pivotal role. Understanding supply and demand dynamics within specific manufacturing subsectors allows investors to identify lucrative opportunities. Second, differentiation matters. Investing in both innovative products and enablers sets companies apart. Finally, gaining insights from both customer and service provider perspectives provides a holistic view, enabling better decision-making.
- Double Down on Quality Control and Compliance. Quality control is non-negotiable. Investors should prioritize adherence to regulations and learn from warning letters issued by regulatory bodies. Rigorous due diligence ensures thorough inspections of all elements. Additionally, strong quality agreements between companies and CDMOs foster trust and mitigate risk. These agreements outline roles, responsibilities, and communication channels, creating a compliant and collaborative relationship.
- Stay Up to Date on the BIOSECURE Act and Manufacturing Trends. The BIOSECURE Act, currently in committee in the US House of Representatives, significantly impacts the industry. It prohibits federal agencies from contracting with biotechnology companies doing business with specific Chinese-based firms. As a result, repatriation trends are emerging in manufacturing. However, the challenge lies in the intricacies of implementation details. Companies must balance onshoring costs without causing drastic price increases. Amid these shifts, maintaining quality and efficiency remain paramount.

Key Takeaways | Contract Research Organizations (CROs)
ARTICLE
Key Takeaways | Contract Research Organizations (CROs)
July 16, 2024
Read time: 6 min
During this session, the panelists discussed the current market outlook for CROs and the key differentiators making them attractive to private equity investors, such as therapeutic area (TA) specialization, their ability to ensure diversity in clinical trials and the integration of artificial intelligence (AI) into their value offerings. They also discussed how the expectations of CRO customers – primarily large pharmaceutical companies – are rising, with a renewed focus on speed and quality in trial execution.
Session panelists:
- Paul Gadiock, Partner, McDermott Will & Emery
- Jeanne Hecht, CEO and Chairwoman of the Board, Lexitas
- John Kerins, Managing Director, Cain Brothers
- Natasha Latif, Principal, The Vistria Group
- Justin Sabet-Peyman, Partner and Deal Team Leader, Patient Square Capital
- Dee Anna Smith, CEO, Sarah Cannon
- Moderator: Joel Rush, Partner, McDermott Will & Emery
Top takeaways included:
- CROs Remain Attractive to Private Equity Investors. Following the biotechnology funding winter, capital markets have bounced back well from a funding standpoint and investor interest in CROs has since grown. Beyond market reasons, this is in part due to the shift by pharmaceutical companies toward outsourcing clinical trial management to CROs. It’s also in part due to an increase in study starts as biopharmaceutical companies seek to refresh pipelines after product patents expire. In general, completing clinical trials is mission critical service for pharma companies that have poured significant resources into research and development and into bringing a product to market, so the uptick in investing in CROs is likely to continue.
- Investors Look for Red Flags When Conducting Due Diligence. Because CROs are service businesses, an investment firm interested in a CRO will first look at the talent and capabilities of the organization’s leadership team. Firms are more likely to invest if they are familiar with the CRO’s leaders or have backed them before. Second, when conducting their due diligence, investors will spend significant time assessing whether there are any question marks associated with a company’s culture of compliance (e.g., the investor will look into corrective and preventive actions if inspections have occurred) or whether there are any suspicious deviations in reporting not identified up front. Other factors investors will investigate and consider include the CRO’s thesis that the firm would be underwriting, the CRO’s consistency across authorization policies and, if it’s a smaller CRO, how it competes against the larger players in the market and ascertaining the smaller CRO’s “right to win” in that TA pipeline.
- CRO Customer Expectations Are Rising. Like private equity investors, pharmaceutical customers have increasingly high expectations for the CROs they contract with, particularly regarding the speed and quality of the trials conducted by the CRO. It is no longer just about when the first patient is dosed, but when the last patient is treated. In today’s environment, big pharmaceutical companies are especially frugal with their assets and tend to expect more efficiency from their CROs because of technology improvements that allow the CROs to report and match differently. Overall, however, customers still seek the same thing they’ve always wanted: a well-designed clinical trial executed to the highest quality standards to meet regulatory agency approval and eventually commercial launch.
- Both TA Specialist and Generalist CROs Can Deliver Value to Customers. TA expertise is foundational and critical to any clinical study, but certain TAs, such as oncology, are more likely to have specialist CROs than others. TA-specialty CROs have the advantage of deep key opinion leader networks, allowing them to move from Phase I to Phase III quickly. By contrast, larger generalist CROs offer a broad set of offerings and resources, giving them an advantage in logistics management, and are therefore more likely to win a Phase III trial. However, TA specialization is not the only thing CROs should strive to be experts in. To compete in today’s market, CROs should also master the functional design of trials, biostatistics and data capabilities on an international scale. There are paths to success for both specialty and generalist CROs.
- CROs Can Integrate AI Into Their Businesses to Optimize Efficiency. Because scale matters, TA-specialty CROs can optimize logistics management by automating certain functions with AI. The objective in so doing is to reduce the administrative burden on skilled individuals and allow them to realize their potential as thought partners. Companies have successfully implemented AI for a variety of use cases, including in medical writing, in pharmacovigilance and product safety to conduct literature searches, and in drafting documents for annual Investigational New Drug Application reporting updates. Newer use cases currently being tested include drafting trial plans, creating cost proposals and patient matching (including data modeling for predictive biomarkers). AI can reduce CRO operating costs and allow CRO personnel to do what they are best at, which is thoughtfully optimizing and executing clinical trials, but AI’s full potential is still to be determined.
- Achieving Diversity in Trials Remains a Challenge. Recent regulatory guidance instructing companies to enroll a diverse set of patients in trials is laudable and will help the industry understand how its products are being used in the real world. But challenges persist in increasing diversity both because of an unmet need for health centers that do research in underrepresented areas and because of a lack of trust in clinical care generally. As an industry, it is critical that stakeholders have tough conversations to find ways to reach these patients, such as improving communication to make potential patients aware of trials for which they are candidates, ensuring informed consent is properly translated and sending mobile clinics to underserved areas.

Key Takeaways | Pharma and MedTech Services Market Overview With McKinsey & Company
ARTICLE
Key Takeaways | Pharma and MedTech Services Market Overview With McKinsey & Company
July 16, 2024
Read time: 3 min
During this session, McDermott Partner Kristian Werling and Jeff Smith, a senior partner at McKinsey & Company, shared insights across the pharma and MedTech services industries, including key trends and opportunities shaping the markets, their impact on private investors and portfolio companies, and forward-looking considerations for players in the space.
Top takeaways included:
- Increased Market Complexity and a Newfound Focus on Research and Development (R&D) Cost Effectiveness Will Produce Diverging Results. Compared to a decade ago, today’s pharma and MedTech services markets are highly complex because of continuing outsourced provider penetration, policy changes such as the Inflation Reduction Act of 2022 and a recent focus on R&D cost effectiveness by pharmaceutical companies. Thus, industry players can expect strong but not universal winners. Additionally, challenges resulting from this complexity will lead to losses for others. Pharma and MedTech services groups, like contract research organizations (CROs), can take advantage of this complexity by specializing to secure a select portion of the market.
- Commercialization Is Key to Achieving the Full Potential of Recently Launched Assets. Pipelines are diversifying in modality and dosage, with fewer new small molecule assets and an increasing rollout of cutting-edge products (e.g., cell and gene therapy). At the same time, a revenue gap is emerging from the patent expirations of large blockbuster assets. Commercialization efforts, particularly medical communications and market access, will be critical to unlocking the potential of newer assets and closing said revenue gap. For example, as the power of pharmaceutical sales representatives declines, having conversations with physicians about clinical trial data is rising in importance.
- Artificial Intelligence (AI) Presents an Opportunity to Transform the Way of Working Across the Value Chain. Several experiments and pilots are underway to evaluate applications of AI throughout the pharma and MedTech services industries, including efforts to automate time-consuming tasks for highly-trained individuals. Despite these significant investments, AI’s utility in this space remains to be seen with no clear winners in sight. However, standing still is not an advisable option, especially for service providers. Those who do not invest are likely to be disappointed in the years ahead.
- Pharma and MedTech Services Remain Bullish in the Long Term. Despite relatively new market complexities and the resulting challenges, the sustainability of pharma and MedTech services are rooted in innovation, with significant recent scientific advancements propelling the market forward. Pipelines have expanded in a near-linear fashion in terms of spend (perhaps more emphatically in the number of pipeline assets) and biotech funding is stabilizing close to pre-pandemic levels, rendering the overall long-term market outlook positive.

FDA Pushes to Diversify Clinical Studies, Releases Draft Industry Guidance
ARTICLE / CLIENT ALERT
FDA Pushes to Diversify Clinical Studies, Releases Draft Industry Guidance
July 15, 2024
Read time: 7 min
On June 26, 2024, the US Food and Drug Administration (FDA) released its much-anticipated draft guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. The draft guidance describes which clinical studies would require diversity action plans, what clinical study sponsors should include in their plans, and when FDA may determine that a sponsor can waive the diversity action plan requirement. The draft guidance was issued pursuant to FDA’s obligation under the 2022 Food and Drug Omnibus Reform Act (FDORA) to update its guidance on diversity action plans. Once finalized, this guidance will replace FDA’s April 2022 draft guidance on diversity plans in clinical studies.
The draft guidance provides insight into the actions that FDA expects clinical study sponsors to take to address the historical underrepresentation of certain populations based on age, ethnicity, biological sex and race in clinical studies. It also provides sponsors and other interested parties the opportunity to potentially shape FDA’s expectations by submitting comments on the draft guidance. The obligation to prepare and implement diversity action plans falls primarily on sponsors. However, other stakeholders that support the design and implementation of clinical studies, such as contract research organizations, site management organizations, subject recruitment solution providers and research sites, should consider how the recommendations in the draft guidance may impact their obligations and business strategies.
Comments on the draft guidance must be submitted by September 26, 2024.
Minority and underserved populations have long been underrepresented in clinical studies, leading to disparities in the quality and range of treatment options available to them. Diversity action plans are intended to increase the participation of historically underrepresented populations in clinical studies. FDA’s guidance, consistent with section 3602(a) of FDORA, is primarily focused on plans for adequate representation across age groups, biological sexes, and racial and ethnic groups. However, FDA notes that other characteristics could be important to consider when developing a diversity action plan, such as geographic location, gender identity, sexual orientation, socioeconomic status, physical and mental disabilities, pregnancy status, lactation status and co-morbidity.
Which Clinical Studies Require Diversity Action Plans
According to the draft guidance, diversity action plans would be required for Phase 3 and other pivotal trials (besides bioavailability or bioequivalence studies) for new drugs, including biological products. Most device trials would also require diversity action plans, including those intended to serve as the primary basis for FDA’s evaluation of the safety and effectiveness and benefit-risk determination of the device. If a device study requires submission of an investigational device exemption (IDE) application, the diversity action plan must be included in the IDE application. If a device trial does not require submission of an application for an IDE, the diversity action plan may be submitted with any marketing application (i.e., premarket notification, request for classification or premarket approval application). Diversity action plans are not required for studies exempt from IDE regulations or for device studies that are not designed to collect definitive safety and effectiveness evidence for a specified intended use of a device.
As required by section 3602(c) of FDORA, once FDA’s final guidance is issued, a clinical study sponsor will have to comply with the guidance if the sponsor’s study begins enrollment more than 180 days after the guidance was published. However, FDA does not expect diversity action plans to be submitted for:
- Clinical drug studies with protocols submitted within 180 days following the publication of the final guidance even if enrollment begins more than 180 days after publication of the final guidance.
- Clinical studies of devices received by FDA in IDE applications within 180 days after publication of the final guidance.
- Clinical studies of devices that do not require an IDE application that are approved by an institutional review board or independent ethics committee within 180 days after the publication of the final guidance.
Requirements for Diversity Action Plans
Diversity action plans should include:
- A study sponsor’s goals for enrollment in the study disaggregated by age group, sex, ethnicity and race.
- The sponsor’s rationale for such goals.
- The sponsor’s explanation of how it plans to meet such goals.
An appendix at the end of the guidance lists the elements of a diversity action plan and notes that a diversity action plan generally should not exceed 10 pages (excluding references).
FDA notes that enrollment goals should generally be informed by the prevalence or incidence of the condition in the US population that is intended to use the product and should consider the sponsor’s overall clinical development program. For example, where a sponsor plans multiple clinical studies, the sponsor should work to achieve proportionate representation across all the studies, even if a single study does not have a proportionally representative population. Diversity action plans for multinational studies should include enrollment goals for the entire study, not just the portions of the study carried out in the United States. Notably, while FDA acknowledges that certain development programs, such as rare disease programs, may have a single, small pivotal study with participant cohorts too small to detect differences in safety and effectiveness across the population, FDA does not exempt these programs from submitting diversity action plans.
The rationale for the study’s enrollment goals must provide sufficient detail and analysis to provide an explanation of how the sponsor determined those goals. This may include any background information necessary to understand the condition or disease addressed by the product being studied (e.g., risk factors for the condition, or incidences or prevalence of the condition). It should also describe any data or information that suggests that the safety or effectiveness of the drug or device being studied may vary across the clinically relevant population.
The diversity action plan must also include a description of the strategies the sponsor plans to use to enroll and retain study participants. FDA notes that the diversity action plan should focus on specific measures taken to address enrollment and retention of participants in the study for which the plan is being submitted. Examples of clinical enrollment and retention strategies referenced in the guidance include sustained community engagement, cultural competency and proficiency training for clinical investigators and staff, participant language assistance, strategies that reduce participant burden (e.g., transportation assistance or dependent care services), and the use of decentralized clinical trial tools to reduce the need for in-person visits to the clinical sites by participants. The diversity action plan should also describe how the sponsor intends to monitor enrollment goals throughout the study. The guidance strongly encourages sponsors to share strategies for meeting enrollment goals with the public, including posting such strategies on sponsors’ websites.
Submission and Waivers
The guidance includes details about the timeline and process for submitting a diversity action plan and how FDA will provide feedback on submitted diversity action plans. The draft guidance also lists the factors FDA will consider when weighing a request to waive submission of a diversity action plan, noting that such waivers will be rare. These factors include whether a diversity action plan is necessary based on information about the prevalence of the condition, whether conducting a study in accordance with a diversity action plan would be impracticable, and whether a waiver is necessary to protect public health during a public health emergency.
Key Takeaways
Although this draft guidance provides valuable information about what steps FDA will expect sponsors to take to promote adequate representation across demographic characteristics in study populations, this guidance has not been finalized. Potential study sponsors and other stakeholders have the opportunity to provide feedback on the draft guidance by submitting comments by September 26, 2024.
For more information about the FDA’s draft guidance on diversity action plans and its potential impact on clinical research stakeholders, contact one of the authors or any other member of McDermott’s Food, Drug & Medical Device Regulatory Practice Group.
